What is Technivie?
Technivie (generic: ombitasvir, paritaprevir and ritonavir) is a combination hepatitis C treatment that works by preventing the virus from multiplying in your body. The drug is approved to treat genotype 4 chronic hepatitis C in adults without cirrhosis. Technivie is manufactured by AbbVie, and was approved by the U.S. Food & Drug Administration (FDA) on July 24, 2015.
Technivie Side Effects May Include Liver Disease: FDA Warning
The FDA in October 2015 issued a Drug Safety Communication announcing new label warnings for Technivie and Viekira Pak (another hepatitis C treatment manufactured by AbbVie). According to the agency, side effects of the medications can cause serious liver injury, particularly in patients who have underlying advanced liver disease.
“Our review of adverse events reported to the FDA Adverse Event Reporting System (FAERS) database and to the manufacturer of these medicines, AbbVie, identified cases of hepatic decompensation and liver failure in patients with underlying liver cirrhosis who were taking these medicines,” FDA said. “Some of these events resulted in liver transplantation or death.”
Most cases of liver damage occurred within 1 to four weeks of starting treatment with the drugs. Some patients were contraindicated and doctors prescribed the medications despite existing warnings that use by patients with those conditions was not recommended.
Symptoms of Liver Disease
- Loss of appetite
- Yellow eyes or skin (jaundice)
- Light-colored stools
Effects of Hepatitis C on the Body
Hepatitis C can cause scarring of the liver (cirrhosis). As the disease progresses, symptoms such as skin problems, blood disorders and fever may appear. In the long term, hepatitis C can lead to severe liver damage, liver cancer, and liver failure.
Technivie Side Effects
- Liver disease
- Liver failure
- Hepatic decompensation
- Hepatic failure
- Allergic reactions
- Thinning blood
- Difficulty sleeping
About Class Action Lawsuits
Although we are a nationally recognized class action firm, the Products Liability Litigation Group at our law firm has decided against the filing of a Technivie class action suit, and is currently filing individual claims on behalf of people who took Technivie for genotype 1 chronic hepatitis C infection (including those with compensated cirrhosis) and subsequently developed liver failure, required a liver transplant, or died from liver disease. Serious liver injury must have occurred within 1 to 4 weeks of initiating treatment with Technivie.
Why Our Law Firm Is Filing Individual Lawsuits Opposed To a Class Action
In some instances, a class action may offer some advantages, as they aggregate a large number of individualized claims into one representational lawsuit. The aggregation can increase the efficiency of the legal process, lower the costs of litigation and in some cases offer the solution to a common problem wherein small recoveries do not provide the incentive for any individual or law firm to file an individual lawsuit.
However, a class action suit can also be a detriment to many class members, as they are often forced into a blanket “low ball settlement” and higher attorney fees. At Schmidt & Clark, LLP we understand that our clients are suffering emotionally and economically due to loss of wages and/or high medical bills and we plan to maximize each client’s recovery by filing individual Technivie lawsuits on their behalf.
Do I Have a Technivie Lawsuit?
The Class Action Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Technivie lawsuits. We are handling individual litigation nationwide and currently accepting new liver disease cases in all 50 states.
Free Case Evaluation: Again, if you had liver failure or required a liver transplant, or someone you know died from liver disease after taking Technivie, you should contact our law firm immediately. You may be entitled to a settlement by filing a suit and we can help.